Inovio Pharmaceuticals (INO) Long-Term Debt Issuances (2019 - 2020)

Inovio Pharmaceuticals (INO) posted Long-Term Debt Issuances of $171620.0 for Q2 2020, down 99.82% sequentially from $97.4 million in Q4 2019.

Inovio Pharmaceuticals (INO) Long-Term Debt Issuances (2019 - 2020) Analysis & Trends

Inovio Pharmaceuticals has reported Long-Term Debt Issuances for 2 years, with the latest figure at $171620.0 in Q2 2020.

Quarterly Long-Term Debt Issuances changed N/A year-over-year to $171620.0 in Q2 2020, while the trailing twelve-month figure through Sep 2021 was $171620.0 (down 99.82% YoY) and the FY2020 annual result came in at $171620.0, down 99.82% from the prior year.
Long-Term Debt Issuances eased to $171620.0 in Q2 2020 per INO's latest filing, from $97.4 million in the prior quarter.
Over five years, Long-Term Debt Issuances peaked at $97.4 million in Q4 2019 and troughed at -$75.7 million in Q3 2019.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Issuances (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	-
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	Inovio Pharmaceuticals	96.32 Mn	96.32 Mn	-	-

Download Data